Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $140.00 short put and a strike $130.00 long put offers a potential 10.25% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $140.00 by expiration. The full premium credit of $0.93 would be kept by the premium seller. The risk of $9.07 would be incurred if the stock dropped below the $130.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 39.84 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
3 Best Coronavirus Vaccine Stocks to Buy Right Now
Sun, 20 Sep 2020 10:09:00 +0000
You don't have to take on a huge amount of risk to profit from these solid COVID-19 vaccine leaders.
Johnson & Johnson stock outperforms competitors on strong trading day
Fri, 18 Sep 2020 20:25:00 +0000
COMPANY CLOSE UPDATES Terrence Horan Shares of Johnson & Johnson JNJ rallied 1.37% to $149.18 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.
First Psychedelic Drug Stock Hits $1 Billion In Debut After Upsized IPO
Fri, 18 Sep 2020 20:19:27 +0000
Compass Pathways jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U.S. exchange.
EXPLAINER-When will COVID-19 vaccines be generally available in the U.S.?
Fri, 18 Sep 2020 19:57:08 +0000
U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) this week disagreed about when a COVID-19 vaccine would become widely available. Trump said on Friday that enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts. There are currently no COVID-19 vaccines approved by U.S. regulators, although a handful are in late-stage trials to prove they are safe and effective.
Three-quarters of Americans are worried about the vaccine rush: Pew
Fri, 18 Sep 2020 19:12:11 +0000
Dr. Dara Kass, Yahoo Medical Contributor and Columbia University Associate Professor, joins Yahoo Finance's Akiko Fujita to break down the latest coronavirus developments as the race for a vaccine continues.
Also on Market Tamer…
Follow Us on Facebook